Full-Time
Research Scientist
Ataraxis.ai
11-50 employees
AI-powered prognostic test for breast cancer
Compensation Overview
$120k - $210k/yr
New York, NY, USA
In Person
 AI & Machine Learning (1) |
|---|
- PhD degree in machine learning or statistics.
- Passion for research, attention to detail and ability to drive tasks to completion.
- Excellent understanding of core machine learning concepts.
- Excellent knowledge of the foundations of statistics, linear algebra, probability and machine learning.
- Excellent skills in Python and PyTorch.
- Experience in deep learning and at least one of {self-supervised learning, survival analysis, multi-modal learning, domain adaptation, causal inference, model interpretability, computational pathology}.
- Design and implement novel machine learning models and methods for self-supervised learning, survival analysis, multi-modal learning, causal inference and interpretability.
- Translate machine learning and statistics papers into production-ready code.
- Build robust model evaluation frameworks and monitor model performance.
- Disseminate the results by co-authoring research papers and abstracts.
- Collaborate with a multidisciplinary team of engineers and scientists. Co-mentor our team of research engineers.
Ataraxis.ai creates precision medicine tools for cancer care using artificial intelligence. Its first product, Ataraxis Breast, is an AI-native prognostic test for breast cancer designed to predict patient outcomes more accurately and help doctors personalize treatment plans. Results are delivered quickly, within one business day, through a physician portal or to clinicians. The company differentiates itself by offering an AI-driven prognostic test that aims to set a new standard in molecular diagnostics rather than relying on traditional methods alone, with a focus on rapid, actionable insights for oncology. The goal is to improve how cancer treatment decisions are made by providing fast, data-driven prognostic information to physicians and healthcare providers.
Company Size
11-50
Company Stage
Series A
Total Funding
$24.4M
Headquarters
New York City, New York
Founded
2023
Simplify's Take
What believers are saying
- $20.4M Series A led by AIX Ventures funds Ataraxis Breast U.S. launch in 2025.
- Adopted by top NCI-designated cancer centers and community clinics nationwide.
- Multi-modal data from 10,000+ patients enables expansion to other cancers.
What critics are saying
- Tempus AI's 8M patient records and 95% oncologist partnerships block market share.
- NCCN guidelines exclude AI tests until 2028, mandating Oncotype DX.
- CLIA lab overload causes 4-6 week delays from 2025 digital pathology surge.
What makes Ataraxis.ai unique
- Ataraxis Breast CTX uses Tau causal inference layer to address treatment selection bias.
- Kestrel foundation model pretrained on hundreds of millions of pathology images outperforms standards.
- 1-hour turnaround time uses existing specimens without additional procedures.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Ataraxis.ai who can refer or advise you
Benefits
Company Equity
Company News
Ataraxis AI has launched Ataraxis Breast CTX, an AI-powered test that estimates individualised chemotherapy benefit in breast cancer patients. The platform combines digitised pathology slides with clinical data to predict patient-level outcomes with and without adjuvant chemotherapy. The test was developed using multimodal data from over 10,000 breast cancer patients worldwide and validated across observational studies and randomised controlled trials. It has been adopted by top NCI-designated cancer centres and community clinics across the United States. Ataraxis Breast CTX uses the company's Tau causal inference layer to account for treatment selection bias. The platform aims to identify high-risk patients unlikely to benefit from chemotherapy, helping clinicians make more informed treatment decisions and potentially reduce overtreatment. The test is offered through a CLIA-certified laboratory.
Ataraxis AI has raised $20 million in Series A funding to advance its AI precision medicine platform, focusing on Ataraxis Breast for breast cancer diagnostics. Led by AIX Ventures, the round included investors like Thiel Bio and Founders Fund. The Kestrel model, central to their platform, is 30% more accurate than current standards. The funding will aid in expanding treatment capabilities and developing new AI models, with plans to launch Ataraxis Breast in the U.S. later this year.
Ataraxis, an AI precision medicine company focused on cancer diagnostics, has raised $20 million in Series A funding led by AIX Ventures. Founded by Jan Witowski and Krzysztof Geras in 2022, Ataraxis has now raised a total of $24 million in reported equity funding.
Ataraxis AI, a New York-based startup, secured $20.4 million in Series A funding led by AIX Ventures, with participation from Thiel Bio, Founders Fund, and others. The company, co-founded by Jan Witowski and Krzysztof Geras, uses AI to predict cancer progression and reduce unnecessary chemotherapy. Their breast cancer diagnosis accuracy is 30% higher than standard methods. The funds will aid in expanding to other cancer types and enhancing technology.
The company's first commercial test, Ataraxis Breast, is set to launch in the U.S. market soon, backed by a $20.4 million Series A funding round led by AIX Ventures.